Reacción a "Bladder cancer patients with colour vision deficiency have lower survival rates than those without this visual impairment"

This study puts forward a simple but relevant idea: some people may take longer to detect cancer simply because they do not perceive one of its main symptoms well. Specifically, the authors analyse whether patients with colour blindness have a worse prognosis when they develop bladder cancer, as they may not be able to identify blood in their urine, which is often the first sign of the disease.

Based on the analysis of a large database of electronic medical records, the study shows that patients with bladder cancer and colour vision deficiency have lower survival rates and a higher risk of long-term mortality than those without this visual impairment. The explanation is plausible: bladder cancer usually begins with painless haematuria, i.e., visible blood in the urine without other symptoms. If a person cannot distinguish the colour red well, they may not notice this warning sign and delay consulting their doctor.

It is particularly interesting that this effect is not observed in colorectal cancer. In that case, although blood may also appear in the stool, there are well-established screening programmes and other symptoms, such as abdominal pain or changes in bowel habits, that can alert the patient. This reinforces the idea that the problem is not the cancer itself, but the difficulty in recognising a key symptom when detection depends almost exclusively on visual observation.

That said, it is important to be very cautious when interpreting the results. This is a retrospective study, based on clinical records, with significant limitations. Many people with colour blindness are not officially diagnosed, so the actual number of people affected is likely to be higher. Furthermore, the study does not provide detailed information on the stage of the tumour at the time of diagnosis, making it impossible to confirm directly that the poorer survival rate is due to later diagnosis.

In clinical practice, these data do not imply that bladder cancer screening recommendations should be changed immediately. However, they do call for greater awareness. In people with risk factors (such as being over 70 years of age, using or having used tobacco, and working with industrial paints), knowing about the existence of a colour perception deficit can help to provide them with recommendations on how to better interpret symptoms (even with the collaboration of a family member who periodically checks the subject's urine). In this sense, the study opens up a new line of research on how certain sensory limitations can influence the early diagnosis of cancer and, potentially, its prognosis.